Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC).

被引：21
|
作者：
Park, Jong Chul
Sartor, A. Oliver
Sullivan, Rana
King, Serina
Antonarakis, Emmanuel S.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Tulane Canc Ctr, New Orleans, LA USA
[3] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps5076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5076
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single centre experience
    Gazzilli, M.
    Durmo, R.
    Albano, D.
    Cerudelli, E.
    Panarotto, M.
    Cossalter, E.
    Bertagna, F.
    Giubbini, R.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S628 - S628
  • [32] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [33] P10-1, an open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (rnCRPC) previously treated with sipuleucel-T: Analysis of immunological data
    Beer, T.
    Glode, M.
    Lance, R.
    Greengold, R.
    Haynes, H.
    Sims, R.
    Wang, Y.
    Sheikh, N.
    Corman, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S700 - S700
  • [34] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Radiation therapy (SAbR) for Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Dohopolski, M.
    Watumull, L.
    Mathews, D.
    Gao, A.
    Garant, A.
    Choy, H.
    Ahn, C.
    Timmerman, R. D.
    Courtney, K.
    Hannan, R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E879 - E879
  • [35] A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
    Jha, Gautam Gopalji
    Miller, Jeffrey S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience
    Gazzilli, Maria
    Durmo, Rexhep
    Cossalter, Erika
    Cerudelli, Elisabetta
    Panarotto, Maria Beatrice
    Albano, Domenico
    Bertagna, Francesco
    Giubbini, Raffaele
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (04) : 300 - 307
  • [37] Open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data
    Beer, Tomasz M.
    Glode, L. Michael
    Lance, Raymond S.
    Greengold, Richard H.
    Dela Rosa, Corazon P.
    Sims, Robert Brownell
    Wang, Yang
    Sheikh, Nadeem A.
    Corman, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials
    Small, E. J.
    Higano, C. S.
    Kantoff, P. W.
    Whitmore, J. B.
    Frohlich, M. W.
    Petrylak, D. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    Pili, Roberto
    Haggman, Michael
    Stadler, Walter M.
    Gingrich, Jeffrey R.
    Assikis, Vasileios J.
    Bjork, Anders
    Nordle, Orjan
    Forsberg, Goran
    Carducci, Michael A.
    Armstrong, Andrew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4022 - 4028
  • [40] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345